Covenant Multifamily Offices LLC acquired a new stake in Sanofi SA (NYSE:SNY) during the first quarter, according to its most recent filing with the SEC. The firm acquired 1,949 shares of the company’s stock, valued at approximately $86,000.
Other hedge funds have also bought and sold shares of the company. Quadrant Capital Group LLC increased its position in shares of Sanofi by 259.5% in the fourth quarter. Quadrant Capital Group LLC now owns 12,187 shares of the company’s stock valued at $511,000 after acquiring an additional 8,797 shares during the last quarter. MML Investors Services LLC grew its holdings in Sanofi by 17.6% during the fourth quarter. MML Investors Services LLC now owns 29,297 shares of the company’s stock worth $1,272,000 after purchasing an additional 4,391 shares during the period. Wetherby Asset Management Inc. grew its holdings in Sanofi by 11.1% during the fourth quarter. Wetherby Asset Management Inc. now owns 35,988 shares of the company’s stock worth $1,563,000 after purchasing an additional 3,596 shares during the period. Employees Retirement System of Texas grew its holdings in Sanofi by 288.2% during the fourth quarter. Employees Retirement System of Texas now owns 164,769 shares of the company’s stock worth $7,153,000 after purchasing an additional 122,327 shares during the period. Finally, Nkcfo LLC bought a new position in Sanofi during the first quarter worth about $35,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
A number of equities research analysts have recently issued reports on SNY shares. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating and set a $46.00 price objective for the company. in a report on Saturday, January 26th. TheStreet cut Sanofi from a “b” rating to a “c+” rating in a report on Thursday, February 7th. Finally, HC Wainwright restated a “buy” rating on shares of Sanofi in a report on Thursday, February 28th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $51.00.
NYSE SNY traded up $0.91 on Wednesday, reaching $42.09. The company had a trading volume of 1,438,200 shares, compared to its average volume of 1,027,974. The company has a market capitalization of $103.61 billion, a price-to-earnings ratio of 13.45, a PEG ratio of 2.41 and a beta of 0.67. Sanofi SA has a fifty-two week low of $37.67 and a fifty-two week high of $45.62. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Friday, April 26th. The company reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.34 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. Sanofi’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.28 earnings per share. Research analysts expect that Sanofi SA will post 3.1 earnings per share for the current fiscal year.
The company also recently declared an annual dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 8th will be given a dividend of $1.7395 per share. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a yield of 4.2%. Sanofi’s dividend payout ratio (DPR) is currently 37.38%.
In other news, major shareholder Sanofi sold 131,115 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: What are different types of coverage ratios?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.